Myricanol 5-fluorobenzyloxy ether regulation of survivin pathway inhibits human lung adenocarcinoma A549 cells growth in vitro.
A549 Cells
Adenocarcinoma of Lung
/ drug therapy
Antineoplastic Agents
/ pharmacology
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Diarylheptanoids
/ pharmacology
Down-Regulation
/ drug effects
Humans
Lung Neoplasms
/ drug therapy
Membrane Potential, Mitochondrial
/ drug effects
Survivin
/ drug effects
Up-Regulation
/ drug effects
Antitumor
Cell growth inhibition
Human lung adenocarcinoma A549
Mitochondrial membrane potential
Myricanol 5-fluorobenzyloxy ether
Survivin pathway
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
03 Sep 2020
03 Sep 2020
Historique:
received:
04
03
2020
accepted:
28
08
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
6
5
2021
Statut:
epublish
Résumé
This study aimed to explore the growth inhibitory effect of myricanol 5-fluorobenzyloxy ether (5FEM) and its underlying mechanisms in human lung adenocarcinoma A549 cells in vitro. 5FEM was obtained by the chemical modification of myricanol with fluorobenzyloxy ether at the OH(5) position. The cytotoxicity, cell apoptosis, cell cycle, mitochondrial membrane potential (ΔΨm), scratch test, colony formation, and the expression levels of the key survivin pathway-related genes in A549 were evaluated. 5FEM could significantly inhibit A549 cell growth; induce cell apoptosis; increase G0/G1 population; reduce ΔΨm; inhibit cell migration and colony formation; upregulate caspase-9, P21, and Bax expression levels; and downregulate PARP, survivin, and Bcl-2 expression level. These results enhanced our understanding of 5FEM and aid the discovery of novel myricanol derivatives as potential antitumor agents.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to explore the growth inhibitory effect of myricanol 5-fluorobenzyloxy ether (5FEM) and its underlying mechanisms in human lung adenocarcinoma A549 cells in vitro.
METHODS
METHODS
5FEM was obtained by the chemical modification of myricanol with fluorobenzyloxy ether at the OH(5) position. The cytotoxicity, cell apoptosis, cell cycle, mitochondrial membrane potential (ΔΨm), scratch test, colony formation, and the expression levels of the key survivin pathway-related genes in A549 were evaluated.
RESULTS
RESULTS
5FEM could significantly inhibit A549 cell growth; induce cell apoptosis; increase G0/G1 population; reduce ΔΨm; inhibit cell migration and colony formation; upregulate caspase-9, P21, and Bax expression levels; and downregulate PARP, survivin, and Bcl-2 expression level.
CONCLUSION
CONCLUSIONS
These results enhanced our understanding of 5FEM and aid the discovery of novel myricanol derivatives as potential antitumor agents.
Identifiants
pubmed: 32883260
doi: 10.1186/s12906-020-03062-8
pii: 10.1186/s12906-020-03062-8
pmc: PMC7470448
doi:
Substances chimiques
Antineoplastic Agents
0
Diarylheptanoids
0
Survivin
0
myricanol 5-fluorobenzyloxy ether
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
269Références
Future Med Chem. 2017 Dec;9(18):2117-2127
pubmed: 28819994
J Nat Prod. 2012 Oct 26;75(10):1798-802
pubmed: 23066712
Nat Prod Res. 2011 Jan;25(2):136-40
pubmed: 21246440
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Oncotarget. 2016 Feb 9;7(6):7096-109
pubmed: 26771139
J Zhejiang Univ Sci B. 2019 Jan.;20(1):9-22
pubmed: 30614226
Exp Ther Med. 2012 Jun;3(6):1010-1014
pubmed: 22970008
Planta Med. 2016 Jan;82(1-2):89-96
pubmed: 26485638
Iran J Pharm Res. 2017 Winter;16(Suppl):83-91
pubmed: 29844779
Cancer Res. 2007 Sep 1;67(17):8274-84
pubmed: 17804742
Cell Death Dis. 2018 Mar 19;9(4):425
pubmed: 29556045
Mol Med Rep. 2015 Jan;11(1):639-44
pubmed: 25333812
Int J Mol Sci. 2015 Jan 26;16(2):2717-31
pubmed: 25629230
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Int J Mol Sci. 2015 Jul 29;16(8):17394-421
pubmed: 26230693
Cancer Lett. 2006 Dec 8;244(2):164-71
pubmed: 16621243
Nat Med. 2012 Mar 18;18(4):521-8
pubmed: 22426421
J Nat Prod. 2011 Jan 28;74(1):38-44
pubmed: 21141876
Int J Mol Sci. 2013 Jul 25;14(8):15479-509
pubmed: 23892596
Nat Rev Cancer. 2003 Jan;3(1):46-54
pubmed: 12509766
J Nat Med. 2014 Jul;68(3):521-9
pubmed: 24715263
Cancer Res. 1999 Jul 1;59(13):3143-51
pubmed: 10397257
Apoptosis. 2007 Oct;12(10):1837-46
pubmed: 17624594
Thorac Cancer. 2018 May;9(5):621-629
pubmed: 29575809
Nat Med. 1997 Aug;3(8):917-21
pubmed: 9256286
Cancer Res. 2007 Dec 15;67(24):12007-17
pubmed: 18089832
Phytomedicine. 2014 Sep 25;21(11):1490-6
pubmed: 24939078